In July 2020, Evergreen Therapeutics, Inc. announced its partnership with a leading U.S. laboratory to conduct animal experiment on the effectiveness of PR2005 in treating cytokine storms caused by COVID-19. This trial will provide further evidence of the effectiveness of PR2005 in the treatment of COVID-19.  The laboratory is an independent, non-profit biomedical research institution dedicated to contributing to better health care in the future. Based on each person's unique genetic makeup, the laboratory will discover accurate disease genome solutions, and entrust the global biomedical community with a common mission – to improve human health. The laboratory is a cancer center designated by the National Cancer Institute that hosts the NIH research center on a

In April 2020, Evergreen Therapeutics, Inc. announced the development of a new pipeline, EG-009, to treat the Cytokine Release Syndrome (CRS) caused by the Novel Coronavirus pneumonia. Epidemiologists predict that the world will remain in a pandemic state until June 2021. The virus continues to spread at a slow rate, and intermittent lockdowns are the new normal. It is estimated that 250 million people worldwide will be infected and 1.75 million will die by June 2021.CRS is one of the leading causes of death in COVID-19 patients. CRS is a complex inflammatory response. During the occurrence of CRS, various cytokines such as TNF-, IL-1, IL-6, IL-12, IFN-, IFN-, McP-1, and IL-8 are produced in large quantities in body fluids. CRS can cause acute respiratory distress syndrome and mu

On January 1st, 2020, Dr. Xin Du, former FDA senior reviewer, joined Evergreen Therapeutics Inc. as CEO to comprehensively lead the company's R&D. Dr. Du is a drug R&D expert with more than 20 years of biomedical background, and has a rich combination experience of FDA and industry in drug registration and drug development. Heis familiar with FDA and global regulations on drug development, production, quality management, clinical design and testing. At the same time, he has rich experience in drug R&D, and used to workin multiple multinational and Chinese pharmaceutical companies.Dr. Du Xin was a CMC reviewer in FDA and responsible for reviewing INDs and BLAs of biopharmaceuticals. After that he worked in multinational corporation at Aventis-Pastuer/Sanofi, Wyeth/Pfizer, Novartis,

On September 5th, 2019, Dr. Tao Du, the chairman of Evergreen Therapeutics Inc. , went to the famous Meakins-Christie Laboratories (MCL) of McGill University of Canada, known as the most prestigious respiratory disease institute in the world, for academic exchange activities with his team. Dr. Tao Du and team members discussed collaboration in respiratory disease research with Professor James G Martin, former director of MCL and current leader of internal medicine at McGill University School of Medicine. Both determined that research will be carried out in the fields of respiratory rare diseases and asthma and agreed to have in depth cooperation in clinical trials of respiratory rare diseases.Professor James G Martin has 35 years of clinical and scientific experience in the field